Clinical Trial Update: A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 clinical study of SYS6010 in combination with Osimertinib for locally advanced or metastatic non-small cell lung cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SYS6010
• TAGRISSO (osimertinib)

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: NSCLC | Phase 3 | Status: NOT_YET_RECRUITING